PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Despite recent improvements in treatment modalities, pancreatic cancer remains a highly lethal tumor with mortality rate increasing every year. Poly (ADP-ribose) polymerase (PARP) inhibitors are now used in pancreatic cancer as a breakthrough in targeted therapy. This study focused on whether PARP i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yali, Zheng, Kun, Xiong, Hua, Huang, Yongbiao, Chen, Xiuqiong, Zhou, Yilu, Qin, Wan, Su, Jinfang, Chen, Rui, Qiu, Hong, Yuan, Xianglin, Wang, Yihua, Zou, Yanmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718453/
https://www.ncbi.nlm.nih.gov/pubmed/34975854
http://dx.doi.org/10.3389/fimmu.2021.762989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718453/
https://www.ncbi.nlm.nih.gov/pubmed/34975854
http://dx.doi.org/10.3389/fimmu.2021.762989

Ejemplares similares